跳转至内容
Merck
所有图片(1)

文件

573097

Sigma-Aldrich

STAT3抑制剂III，WP1066

STAT3 Inhibitor III, WP1066, CAS 857064-38-1, is a cell-permeable AG490 tyrphostin analog that acts as a STAT3 pathway inhibitor. A potent anti-tumor agent.

别名:

STAT3抑制剂III，WP1066

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C17H14BrN3O
CAS号:
857064-38-1
分子量:
356.22
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

100

化驗

≥97% (HPLC)

形狀

solid

製造商／商標名

Calbiochem®

儲存條件

OK to freeze
protect from light

顏色

off-white

溶解度

DMSO: 10 mg/mL
ethanol: 5 mg/mL

運輸包裝

ambient

儲存溫度

2-8°C

InChI

1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)/b14-10+/t12-/m0/s1

InChI 密鑰

VFUAJMPDXIRPKO-LQELWAHVSA-N

一般說明

一种细胞渗透性AG 490（目录号658401）酪磷蛋白类似物，在体外培养（使用U87-MG和U373-MG进行生存能力试验时，IC50分别为5.6和3.7 µM；在10 µM时对非肿瘤NHA无抑制作用）和小鼠体内培养中，作为有效的STAT3途径抑制剂和比AG 490更有效的抗肿瘤剂抑制恶性胶质瘤生长。显示在小鼠体内能跨越血脑屏障。也可提供InSolution格式（目录号573129）。
一种细胞渗透性AG 490（目录号658401）酪磷蛋白类似物，在体外培养（使用U87-MG和U373-MG进行生存能力试验时，IC50分别为5.6和3.7 µM；在10 µM时对非肿瘤NHA无抑制作用）和小鼠体内培养中，作为有效的STAT3途径抑制剂和比AG 490更有效的抗肿瘤剂抑制恶性胶质瘤生长。显示在小鼠体内能跨越血脑屏障。

生化／生理作用

主靶
STAT3通路
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
靶标IC50：分别为5.6和3.7 µM，在使用U87-MG和U373-MG的活性试验中，抑制恶性胶质瘤生长

包裝

用惰性气体包装

警告

毒性：刺激性（B）

重構

复溶后，等分并冷冻保存（-20°C）。贮备溶液在-20°C下可稳定保存至多6个月。

其他說明

Iwamaru, A., et al. 2007.Oncogene,26, 2435.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Alicia Haydo et al.
EMBO reports, 24(12), e56964-e56964 (2023-11-08)
Glioblastoma is a very aggressive tumor and represents the most common primary brain malignancy. Key characteristics include its high resistance against conventional treatments, such as radio- and chemotherapy and its diffuse tissue infiltration, preventing complete surgical resection. The analysis of
Meng Chi et al.
Annals of translational medicine, 8(8), 531-531 (2020-05-16)
Dexmedetomidine (DEX), a highly selective α2-adrenergic receptor agonist, has been reported to increase the malignancy of breast cancer cells in vitro and stimulate tumor growth in mice. Transmembrane protease serine 2 (TMPRSS2) demonstrates proteolytic activity, resulting in degradation of the
Eun-Ji Lim et al.
Cell death & disease, 13(4), 417-417 (2022-04-30)
Colorectal cancer (CRC) has a 5-year survival rate of <10%, as it can metastasize to the lungs and liver. Anticancer drugs and targeted therapies used to treat metastatic colorectal cancer have insufficient therapeutic efficacy and are associated with complications. Therefore
In-Hye Ham et al.
International journal of oncology, 61(1) (2022-05-28)
The present study aimed to investigate whether the Janus‑activated kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway is a critical mechanism underlying the cancer‑associated fibroblast (CAF)‑induced chemoresistance of gastric cancer (GC). In addition, the present study tried to
Ahmad Sharanek et al.
Cell reports, 36(9), 109647-109647 (2021-09-02)
Brain tumor stem cells (BTSCs) and intratumoral heterogeneity represent major challenges in glioblastoma therapy. Here, we report that the LGALS1 gene, encoding the carbohydrate binding protein, galectin1, is a key regulator of BTSCs and glioblastoma resistance to therapy. Genetic deletion
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门